Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Longboard Pharmaceuticals (LBPH)
NASDAQ:LBPH
RESEARCH TOOLSreports
Holding LBPH?
Track your performance easily
LBPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.60 - $59.95
Previous Close$59.77
Volume1.29M
Average Volume (3M)1.71M
Market Cap
$2.33B
Enterprise Value$2.05B
Total Cash (Recent Filing)$288.45M
Total Debt (Recent Filing)$3.73M
Price to Earnings (P/E)―
Beta-0.50
Next Earnings
Feb 27, 2025EPS Estimate
-$0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.24
Shares Outstanding39,045,703
10 Day Avg. Volume740,111
30 Day Avg. Volume1,707,072
Standard Deviation0.48
R-Squared0.01
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)8.48
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-28.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-26.22
Forecast
1Y Price Target
$64.00Price Target Upside7.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Longboard Pharmaceuticals News
PremiumCompany Announcements
Longboard Pharmaceuticals Advances Neurological Treatments
Bulls Say, Bears Say
Bulls Say
AcquisitionThe acquisition price of $60 per share represents a 77% premium to LBPH's 30-day volume-weighted average price, indicating strong market confidence in the deal.
Product PotentialBexicaserin is positioned for success in epilepsy with blockbuster potential, supported by an expanded Phase 3 program, which could drive significant future revenue.
Safety ProfileLongboard's bexicaserin has a meaningfully cleaner safety profile compared to competitors, setting it apart in the treatment of developmental and epileptic encephalopathies.
Bears Say
Acquisition ImpactInvestor concerns may have driven the deal to consummate earlier than expected, due to a lack of material value-creating catalysts for Longboard Pharmaceuticals.
Regulatory UncertaintyThere are increasing questions around the inclusion of data from the titration phase of the Ph2 PACIFIC study and its acceptance by the FDA.
Revenue EstimatesUpdated revenue estimates reflect Lundbeck's guidance, which calls for estimated global peak sales between $1.5B-$2.0B, lower than the prior estimate of $2.6B.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LBPH FAQ
What was Longboard Pharmaceuticals’s price range in the past 12 months?
Longboard Pharmaceuticals lowest stock price was $3.60 and its highest was $59.95 in the past 12 months.
What is Longboard Pharmaceuticals’s market cap?
Currently, no data Available
When is Longboard Pharmaceuticals’s upcoming earnings report date?
Longboard Pharmaceuticals’s upcoming earnings report date is Feb 27, 2025 which is in 96 days.
How were Longboard Pharmaceuticals’s earnings last quarter?
Longboard Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.579 by -$0.051.
Is Longboard Pharmaceuticals overvalued?
According to Wall Street analysts Longboard Pharmaceuticals’s price is currently Undervalued.
Does Longboard Pharmaceuticals pay dividends?
Longboard Pharmaceuticals does not currently pay dividends.
What is Longboard Pharmaceuticals’s EPS estimate?
Longboard Pharmaceuticals’s EPS estimate is -$0.63.
How many shares outstanding does Longboard Pharmaceuticals have?
Longboard Pharmaceuticals has 34,436,203 shares outstanding.
What happened to Longboard Pharmaceuticals’s price movement after its last earnings report?
Longboard Pharmaceuticals reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.579. Following the earnings report the stock price went up 0.05%.
Which hedge fund is a major shareholder of Longboard Pharmaceuticals?
Among the largest hedge funds holding Longboard Pharmaceuticals’s share is Farallon Capital Management, L.L.C.. It holds Longboard Pharmaceuticals’s shares valued at 105M.
---
Longboard Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$64.00 (7.02% Upside)
$64.00 (7.02% Upside)
Blogger Sentiment
Neutral
LBPH Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 9.9%
Last 30 Days ▼ 9.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1340.24%
12-Months-Change
Fundamentals
Return on Equity
-46.66%
Trailing 12-Months
Asset Growth
404.56%
Trailing 12-Months
Company Description
Longboard Pharmaceuticals
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its pipeline includes LP352, LP143, and LP659.
---
LBPH Earnings Call
Q2 2024
0:00 / 0:00
---
LBPH Stock 12 Month Forecast
Average Price Target
$64.00
▲(7.02% Upside)
Technical Analysis
Aquestive Therapeutics
―
Kiniksa Pharmaceuticals
―
Pliant Therapeutics
―
Bioxcel Therapeutics
―
Best Analysts Covering LBPH
1 Year
1 Year Success Rate
21/21 ratings generated profit
1 Year Average Return
+203.28%
reiterated a buy rating last month
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +203.28% per trade.
---